Bone Biologics (Nasdaq: BBLG) is a clinical-stage company developing differentiated regenerative medicine therapies for bone, primarily targeting the $3.0 billion spinal fusion market. Their lead product, NB-1, utilizes a proprietary recombinant protein called NELL-1 that is designed to act later in the bone formation pathway to support targeted bone growth with an advantageous safety profile. This is especially critical for “hard healers” who struggle with effective bone regeneration. The mechanistic specificity of NELL-1 represents a critical technology innovation differentiator.
The company is strategically targeting a multibillion-dollar spinal fusion market opportunity by focusing on a clinically underserved and economically significant segment: “hard-to-heal” patients. This cohort—comprising smokers, diabetics, and obese individuals—represents a large and growing proportion of surgical demand, yet experiences disproportionately poor outcomes due to impaired bone regeneration.
From a business strategy perspective, this positioning reflects:
- A segmented market-entry model, prioritizing high unmet need over broad competition
- A value-based innovation thesis, where improved clinical outcomes translate directly into reduced revision surgeries and healthcare costs
- A differentiated reimbursement narrative, as success in difficult populations can justify premium pricing
By quantifying the prevalence of these patients (e.g., >30% smokers, >35% obese), the company emphasizes that this is not a niche—but rather a structurally underserved majority segment.
The company currently has a 30-subject pilot clinical study underway in Australia, which is laying the groundwork for a U.S. pivotal study. To learn more, Digital Journal spoke with the company’s CEO Jeffrey Frelick. Frelick’s background—spanning clinical science, diagnostics, investment banking, and equity research—aligns well with the company’s strategy:
- Ability to translate clinical innovation into commercial narratives.
- Strong understanding of capital markets and investor expectations.
- Experience in technology evaluation and positioning.
This leadership profile supports:
- Effective capital raising strategies.
- Clear strategic articulation to stakeholders.
- Data-driven portfolio prioritization.
If clinical data continues to support early findings, Bone Biologics has the potential to transition from a single-product company to a category-defining leader in regenerative orthopedics, with broader implications for how biologics are deployed across musculoskeletal medicine.
Digital Journal: Can you provide a brief overview of Bone Biologics and the unmet clinical challenges the company is aiming to address for “hard healers” within the spinal fusion market?
Jeffrey Frelick: Bone Biologics Corporation is developing differentiated orthobiologic products targeting the multibillion-dollar spinal fusion market. We are advancing regenerative medicine therapies that build upon the proprietary NELL-1 recombinant protein to provide faster, targeted bone regeneration. Currently, we are evaluating our lead product, NB-1, in a pilot clinical study in Australia to assess safety and effectiveness. The primary unmet clinical need we are addressing surrounds “hard healers,” specifically smokers, diabetic, and/or obese patients, who are at a higher risk for pseudoarthrosis due to a diminished biological capability to produce bone. Literature demonstrates that these “hard healers” are prevalent in the spine fusion population, with smokers consisting of 32.5%, diabetics 18.8%, and obese 35.2% of lumbar fusion patients. Traditional orthobiologic solutions are unable to increase fusion rates in this population, which is a critical gap we are working to fill.
DJ: What differentiates your lead product candidate, NB-1, and its proprietary recombinant NELL-1 protein from conventional orthobiologic treatments currently available?
Frelick: Traditional orthobiologic solutions are inert scaffolds generally comprised of ceramics or allograft, and their mechanism of action is passive, involving osteoconduction where bone cells simply migrate into the scaffold. In contrast, rhNELL-1 is an active component that is osteopromotive. Our lead product candidate, NB-1, combines this rhNELL-1 protein with demineralized bone matrix (DBM) to provide controlled bone regeneration. Osteopromotive NB-1 increases bone formation and the incidence of spinal fusion compared to the inert carrier alone, which has been demonstrated by independent studies and several publications. In preclinical large animal models, rhNELL-1 increased the relative frequency of fusion success by 37.5 percentage points compared to the control.
DJ: Can you explain how NELL-1’s mechanism of action supports targeted bone growth while minimizing the inflammatory responses often seen with alternative therapies?
Frelick: NELL-1’s mechanism of action utilizes attachment to a cellular receptor followed by intracellular signaling that is strictly targeted to bone formation. rhNELL-1 enhances bone formation by upregulating Runx2, which is the master transcriptional activator of bone formation. Because Runx2 is only active in bone cells, rhNELL-1 promotes bone formation in a target-specific fashion (i.e., only increasing bone formation in the presence of existing bone), which may help limit unwanted bone formation in surrounding skeletal muscle. Furthermore, NELL-1’s signaling pathway does not induce inflammation. This was demonstrated in a rat bone study where treatment with NELL-1 elicited no inflammatory response, in stark contrast to the positive control (BMP-2) that induces local inflammation. This differentiated approach forms bone without a significant inflammatory response, potentially offering advantages over other approaches that have been associated with complications such as swelling and ectopic bone growth.
DJ: How was the NB-1 convenience kit developed to fit seamlessly into existing surgical workflows without disrupting current preparation procedures?
Frelick: We intentionally designed our system so that the surgical procedure remains exactly the same for physicians, requiring no change to current orthobiologic preparation protocols. A vial of rhNELL-1 and DBM will be sold in a convenience kit and mixed in the operating room. The delivery of NB-1 is the same as has been routinely performed for commercially utilized allograft demineralized bone matrix (DBM) and DBX for over 20 years. The only operating room preparation difference between NB-1 and DBM/DBX is the addition of rhNELL-1, which is a process comparable to the standard hydration step. A delivery device will allow the surgeon to easily reconstitute the NELL-1 with the DBM putty just prior to implantation into the cage. Additionally, we recently announced that the validated shelf life of our rhNELL-1 protein product has been extended to 29 months, which provides greater scheduling latitude across our clinical and supply chain operations without impacting the surgical workflow.
DJ: What does the company’s regulatory pathway entail, particularly following the FDA’s indication that NELL-1 will be reviewed as a device-drug combination product?
Frelick: Bone Biologics has a clearly defined and efficient regulatory pathway following PreSubmission discussions with the FDA. The U.S. FDA indicated NELL-1 will be reviewed as a device/drug combination product under a Premarket Approval (PMA) application, which is a faster and more efficient process than a New Drug Application (NDA) filing. The primary review center is CDRH (medical devices), with CDER (drugs) consulting for the review of the recombinant protein Chemistry, Manufacturing and Controls. Commercial approval requires a pilot clinical study (analogous to a Phase I-II trial) followed by a pivotal clinical study (analogous to a Phase III trial). Our pilot clinical study is currently ongoing in Australia, and the FDA has indicated that data generated from this Australian study is acceptable and will be reviewed prior to initiating a pivotal clinical study in the United States.
DJ: Looking ahead, how do you view the long-term opportunity to expand these therapies into the trauma and osteoporosis markets?
Frelick: While our current clinical focus and development efforts are singularly focused on bone regeneration in spinal fusion procedures, we hold technology rights for both trauma and osteoporosis applications. Beyond the $3.0 billion global orthobiologics market for spine fusion, we have long-term expansion potential into the $8 billion trauma market and the $11 billion osteoporosis market. Because the spine is one of the most challenging healing environments in the body, we believe that demonstrating success in our spine fusion studies will help pull along these additional clinical applications. For osteoporosis specifically, preclinical systemic administration of NELL-1 in mice has already shown a marked anabolic effect, demonstrating its future potential for osteoporosis therapy.